[Immunotherapeutic treatment for metastatic renal carcinoma].
Immunotherapy management for advanced renal carcinoma has awaken a growing interest over the last few years. Based on Atzpodien's studies, in December 1994 a protocol was initiated in our centre for the treatment of metastatic renal carcinoma, using subcutaneous alpha interferon, subcutaneous Interleukin-2 and endovenous 5-Fluorouracil. The present report analyzes all six cases included in the protocol and their results.
Hidalgo Pardo
F
F
Servicio de Urología, Hospital Son Dureta, Palma de Mallorca.
Gutiérrez Sanz-Gadea
C
C
Rebassa Llull
M J
MJ
García Bueno
J M
JM
Mus Malleu
A
A
Losada González
G P
GP
Ozonas Moragues
M
M
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007167:Immunotherapy; D016898:Interferon-alpha / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged
D016898:Interferon-alpha; D007376:Interleukin-2; D005472:Fluorouracil
Tratamiento inmunoterápico para el carcinoma renal metastásico.